Eukon brings two new cardiology technologies to Italy: agreements with Shenqi and Cardiac Dimensions

Eukon is accelerating medical innovation and announcing two new partnerships that will mark a turning point for interventional cardiology in Italy. The company, specializing in the development and distribution of cutting-edge technologies, has signed an agreement with Shenqi Medical to bring LaaGuarder, a left atrial appendage closure device designed for at-risk patients, to Italy. ictus, which promises safety, effectiveness and competitiveness.

But that's not all. At the same time, Eukon has strengthened its international network by becoming the main partner in Italy of Cardiac Dimensions, a US pioneer in the treatment of mitral regurgitation. With the Carillon® Mitral Contour System®, the first percutaneous transvenous annular remodeling device, validated by clinical studies and already included in the most recent guidelines, the company is bringing to the Italian market a solution that expands therapeutic options for patients and physicians.

"With Shenqi and Cardiac Dimensions, Eukon is taking another step forward in its mission: to bring the most advanced solutions for the treatment of cardiovascular diseases to Italy," explained CEO Claudia Mugnoz. "Thanks to these collaborations," she added, "we can offer new options to clinicians and better life prospects to patients."

Along the same lines Gennaro Broya of Lucia, president of Conflavoro PMI Sanità and founder of Eukon, who emphasized the partnerships' impact not only on healthcare but also on the economy: "This achievement demonstrates that it is often small and medium-sized enterprises that capture the attention of international giants and bring concrete innovation to our hospitals. This is an important step toward a more modern healthcare system that is more responsive to patient needs. Burdening SMEs with burdens like payback or unsustainable tax burdens weakens those who bring real value to the country."